AstraZeneca creates digital health unit, with big-name partnerships already in place
Dive Brief: AstraZeneca’s new health-tech business, Evinova, launched Monday, with several big-name partnerships already in place and a goal to “better meet the needs of healthcare professionals, regulators and patients.” Evinova’s main focus will be helping to optimize clinical trials…
Bristol Myers faces FDA delay on cancer cell therapy decision
Dive Brief: The Food and Drug Administration plans to hold an advisory panel review of Bristol Myers Squibb and 2seventy bio’s application for an expanded approval of their multiple myeloma cancer therapy Abecma, the partner companies said Monday. As a…
Bayer ends large blood thinner trial for ‘inferior efficacy’
Bayer is stopping a large clinical trial testing its experimental blood thinner asundexian in people with irregular heartbeats because it didn’t work as well as Bristol Myers Squibb’s Eliquis, the company said Monday. Shares in the German drugmaker fell by…
Medtronic CEO downplays impact of obesity drugs on procedures, devices
By the numbers FY2024 Q2 revenue: $7.98 billion 5.3% year-over-year growth Medical Surgical revenue: $2.14 billion 7% year-over-year growth Diabetes revenue: $610 million 9.7% year-over-year growth Medtronic CEO Geoff Martha on Tuesday became the latest medtech executive…
Roche’s Genentech partners with Nvidia in AI drug deal
Roche’s Genentech unit is partnering with computing giant Nvidia in a multiyear deal that highlights the pharmaceutical industry’s growing hopes of using artificial intelligence to speed up the process of designing and developing new drugs. By collaborating with Nvidia, Genentech…
Quotient emerges from Flagship with plan to explore somatic mutations
Dive Brief: Quotient Therapeutics, a biotechnology company focused on studying the role of somatic mutations in disease, emerged from stealth Tuesday with $50 million from Flagship Pioneering. The company aims to use single-cell gene sequencing and computational techniques to parse…
Merck to buy private biotech Caraway in neuroscience deal
Dive Brief: Merck & Co. will pay as much as $610 million to acquire private biotechnology company Caraway Therapeutics in a deal that expands Merck’s research presence in neurodegenerative disease. Announced Tuesday, the deal involves an undisclosed upfront payment along…
Freeline, after cuts, agrees to take-private deal with Syncona
Freeline Therapeutics, a U.K.-headquartered developer of gene therapies, has agreed to be taken private in a deal with British investment firm Syncona, the companies announced Tuesday. Syncona, which already owned more than half of Freeline, will pay $6.50 per American…
Flagship-backed microbiome biotech Evelo to shut down
Evelo Biosciences, a biotechnology company launched by Flagship Pioneering to develop microbiome drugs, is shutting down, according to a regulatory filing. The move follows setbacks for the company, which was testing its lead drug candidate for inflammatory skin conditions. That…
Are cake Delta 8 disposables safe?
cake Delta 8 disposables safe Delta 8 is a cannabinoid that produces intoxicating effects when vaped. It’s an analog of Delta 9 THC, the primary psychoactive compound in cannabis plants. Before buying a Cake Delta 8 cartridge, make sure it’s…